


- 23 -

WHAT IS CLAIMED IS:

1. A soft capsule comprising:
 - (a) a shell comprising gelatin, wherein said shell encapsulates
 - (b) a pharmaceutical formulation comprising an active compound having the structural formula



and a pharmaceutically acceptable carrier.

2. The capsules of claim 1 wherein the pharmaceutical formulation is a solution of the active compound in a pharmaceutically acceptable carrier.

3. The capsules of claim 1 wherein the pharmaceutical formulation is a suspension containing solid particles of the active compound in a pharmaceutically acceptable carrier.

- 24 -

4. The capsules of claim 3 wherein the active compound is present as a free drug.

5. The capsules of claim 1 wherein the active compound is present in an amount of about 1% to about 45% by weight of the pharmaceutical formulation.

6. The capsules of claim 1 wherein the pharmaceutically acceptable carrier comprises a pharmaceutically acceptable solvent.

7. The capsules of claim 6 wherein the pharmaceutically acceptable solvent is selected from the group consisting of polyethylene glycol 400, propylene glycol, glycofurol, and mixtures thereof.

8. The capsules of claim 6 wherein the pharmaceutically acceptable carrier further comprises a polyvinylpyrrolidone.

9. The capsules of claim 2 wherein the pharmaceutical formulation comprises about 2% to about 2.8% by weight of the active compound, about 3% to about 8% by weight propylene glycol, and about 90% to about 95% by weight polyethylene glycol 400.

10. The capsules of claim 3 wherein the pharmaceutically acceptable carrier comprises a pharmaceutically acceptable solvent and a suspending agent.

- 25 -

11. The capsules of claim 10 wherein the pharmaceutically acceptable solvent is selected from the group consisting of polyethylene glycol 400, propylene glycol, glycofurol, a C₈-C₁₀ monoglyceride, and mixtures thereof.

12. The capsules of claim 10 wherein the suspending agent comprises a saturated polyglycolyzed glyceride.

13. The capsules of claim 10 wherein the suspending agent comprises a saturated polyglycolyzed glyceride and the solvent comprises C₈-C₁₀ monoglycerides.

14. The capsules of claim 10 wherein the pharmaceutically acceptable carrier further comprises a surfactant.

15. The capsules of claim 3 wherein the pharmaceutical formulation comprises about 3% to about 8% by weight of the active compound, about 5% to about 8% by weight propylene glycol, about 10% to about 60% by weight of C₈-C₁₀ monoglycerides, and about 30% to about 75% by weight of a polyglycolyzed glyceride.

16. The capsules of claim 1 wherein the active compound is present in an amount of about 1 to about 20 mg per capsule.

- 26 -

17. The capsules of claim 1 wherein the active compound is present in an amount of about 2 to about 20 mg per capsule.

18. The capsules of claim 1 wherein the active compound is present in an amount of about 5 to about 15 mg per capsule.

19. The capsules of claim 1 wherein the active compound is present in an amount of about 10 mg per capsule.

20. A method of treating sexual dysfunction in a patient in need thereof comprising administering to the patient a capsule of any of claims 1 to 19.

21. The invention as hereinabove described.

